Adam Robertson

Company: Hemispherian

Job title: CSO

Seminars:

Plenary Panel: How Do You Select the Best Model for Your Study & Achieve the Best Balance of Preclinical Tumour Models? 8:30 am

Unveiling how integrating multiple tumour models can enhance predictive accuracy and improve translational relevance Uncovering actionable insights into streamlining tumour model research amidst increasing financial and logistical pressure Addressing the critical need for next-generation tumour models that better mimic clinical outcomes, accelerating the path to successful therapiesRead more

day: Conference Day One

Targeted DNA Damage in Glioblastoma: Efficacy, Toxicology, and Clinical Advancements 11:30 am

Exploring innovative mechanism of action through targeted DNA damage to selectively kill cancer cells Discussing results from orthotopic glioblastoma xenograft studies showing significant efficacy over standard therapies Highlighting progress in clinical readiness with completed toxicology studies and upcoming trialsRead more

day: Conference Day Two

Panel: Are GEMMs Worth the Investment? Evaluating Their Value in Cancer Research 1:30 pm

Evaluating whether the significant financial and logistical investment in GEMMs yields reliable, actionable insights that justify their use in drug discovery Investigating the gap between GEMM preclinical results and clinical trial outcomes, questioning their true predictive capacity for human patient responses Discussing the evolving role of GEMMs in precision oncology, exploring their potential to refine…Read more

day: Conference Day Two